TNFα inhibitor may be effective for severe COVID-19: learning from toxic epidermal necrolysis.

abstract：OBJECTIVE:To identify potential predictors for invasive and non-invasive mechanical ventilation in coronavirus disease 2019 (COVID-19) patients. METHODS:This study retrospectively analyzes data of 516 patients with confirmed COVID-19, who were categorized into three groups based on which mechanical ventilation method ...

journal_title：Therapeutic advances in respiratory disease

authors： Li W,Lin F,Dai M,Chen L,Han D,Cui Y,Pan P

更新日期：2020-01-01 00:00:00

abstract：:In recent years in the management of pulmonary arterial hypertension (PAH), endothelin receptor antagonists (ERAs) represent a well-established class of therapeutic agents with clear beneficial effects. Macitentan (Opsumit®), a dual ERA optimized for efficacy and safety, is the newest drug in the class. Macitentan pre...

journal_title：Therapeutic advances in respiratory disease

authors： Steriade A,Seferian A,Jaïs X,Savale L,Jutant EM,Parent F,Sitbon O,Humbert M,Simonneau G,Montani D

更新日期：2014-06-01 00:00:00

abstract：INTRODUCTION:Since its introduction to the market in 2016, selexipag has been an alternative oral therapy among both treatment-naïve patients and those with mono or dual therapy failure; however, limited information is available regarding the presentation and management of patients with pulmonary arterial hypertension ...

journal_title：Therapeutic advances in respiratory disease

authors： Highland KB,Hull M,Pruett J,Elliott C,Tsang Y,Drake W

更新日期：2019-01-01 00:00:00

abstract：RATIONALE:Symptom relief is a key treatment goal in patients with chronic obstructive pulmonary disease (COPD). However, there are limited data available on the response to bronchodilator therapy in patients at low risk of exacerbations with different levels of symptom severity. This study compared treatment responses ...

journal_title：Therapeutic advances in respiratory disease

authors： Vogelmeier CF,Kerwin EM,Bjermer LH,Tombs L,Jones PW,Boucot IH,Naya IP,Lipson DA,Compton C,Barnes N,Maltais F

更新日期：2020-01-01 00:00:00

abstract：BACKGROUND:Endoscopic lung volume reduction coil (LVRC) treatment is a therapeutic option for selected patients with advanced emphysema. The effects and the safety of endoscopic lung volume reduction in patients with very low forced expired volume in one second (FEV1) remain to be determined. This study was conducted t...

journal_title：Therapeutic advances in respiratory disease

authors： Simon M,Harbaum L,Oqueka T,Kluge S,Klose H

更新日期：2018-01-01 00:00:00

abstract：BACKGROUND:Disease severity may change in the first week after acute respiratory distress syndrome (ARDS) onset. The aim of this study was to evaluate whether the reclassification of disease severity after 48 h (i.e. day 3) of ARDS onset could help in predicting mortality and determine factors associated with ARDS pers...

journal_title：Therapeutic advances in respiratory disease

authors： Chiu LC,Lin SW,Liu PH,Chuang LP,Chang CH,Hung CY,Li SH,Lee CS,Wu HP,Huang CC,Li HH,Kao KC,Hu HC

更新日期：2020-01-01 00:00:00

abstract：:Clinical and immunologic tolerance are hallmarks of successful allergen immunotherapy (AIT). Clinical benefits such as reduced symptoms, pharmacotherapy intake and improvement of quality of life persist following cessation of treatment. Successful AIT is associated with suppression of allergic inflammatory cells such ...

journal_title：Therapeutic advances in respiratory disease

authors： Kappen JH,Durham SR,Veen HI,Shamji MH

更新日期：2017-01-01 00:00:00

abstract：OBJECTIVES:This study evaluated the effectiveness of behavioral interventions (brief counseling, nonspecific psychological support in groups - NSGS and cognitive behavioral group therapy - CBGT) in combination with bupropion SR for smoking cessation in the field, through a smoking cessation clinic. METHODS:Two-hundred...

journal_title：Therapeutic advances in respiratory disease

authors： Rovina N,Nikoloutsou I,Katsani G,Dima E,Fransis K,Roussos C,Gratziou C

更新日期：2009-12-01 00:00:00

abstract：OBJECTIVES:To describe the health-related quality of life (HRQL) in a cohort of COPD patients recruited in primary care and identify the variables of the patients and the treatment associated with impaired HRQL. METHOD:Multicenter, observational study of patients with COPD recruited in Primary Care centers. Data regar...

journal_title：Therapeutic advances in respiratory disease

authors： Miravitlles M,Molina J,Naberan K,Cots JM,Ros F,Llor C,EVOCA study.

更新日期：2007-12-01 00:00:00

abstract：BACKGROUND:Comorbidities probably contribute to the increased mortality observed among subjects with chronic obstructive pulmonary disease (COPD), but sex differences in the prognostic impact of comorbidities have rarely been evaluated in population-based studies. The aim of this study was to evaluate the impact of com...

journal_title：Therapeutic advances in respiratory disease

authors： Sawalha S,Hedman L,Backman H,Stenfors N,Rönmark E,Lundbäck B,Lindberg A

更新日期：2019-01-01 00:00:00

abstract：:Angiogenesis is a driving force of a tumor's development. Targeting this process is an attractive option, as this is a feature shared by most of the solid tumors. A lot of antiangiogenic drugs have been developed following this path, including bevacizumab, sorafenib, sunitinib, vandetanib, ramucirumab, motesanib and m...

journal_title：Therapeutic advances in respiratory disease

authors： Caglevic C,Grassi M,Raez L,Listi A,Giallombardo M,Bustamante E,Gil-Bazo I,Rolfo C

更新日期：2015-08-01 00:00:00

abstract：OBJECTIVES:Pharmacologically mediated bronchodilation is important in the management of asthma, and is primarily achieved with β₂-agonists. Novel compounds should preferably have a longer duration of action and a better systemic side effect profile than established alternatives at comparable peak bronchodilation. This ...

journal_title：Therapeutic advances in respiratory disease

authors： Bjermer L,Rosenborg J,Bengtsson T,Lötvall J

更新日期：2013-10-01 00:00:00

abstract：BACKGROUND:Bacterial pneumonia is a major cause of acute respiratory distress syndrome (ARDS) requiring extracorporeal membrane oxygenation (ECMO) support. However, it is unknown whether the type of pneumonia, community-acquired pneumonia (CAP) versus hospital-acquired pneumonia (HAP), should be considered when predict...

journal_title：Therapeutic advances in respiratory disease

authors： Park C,Na SJ,Chung CR,Cho YH,Suh GY,Jeon K

更新日期：2019-01-01 00:00:00

abstract：:Asthma is one of the most common respiratory disorders in clinical practice, affecting up to 13% of people worldwide. Inflammation is the most important component of asthma and inhaled corticosteroids (ICS) are recommended as the first line controller treatment for patients of all ages. Treatment with corticosteroids ...

journal_title：Therapeutic advances in respiratory disease

authors： del Giudice MM,Pezzulo A,Capristo C,Alterio E,Caggiano S,de Benedictis D,Capristo AF

更新日期：2009-10-01 00:00:00

abstract：OBJECTIVE:The ultra-short course preseasonal allergy vaccine, containing the adjuvant monophosphoryl lipid A (MPL), is effective in treating allergic symptoms; however, the efficacy in controlling asthmatics symptoms has not been fully demonstrated. We aimed at evaluating whether the ultra-short preseasonal course of i...

journal_title：Therapeutic advances in respiratory disease

authors： Scichilone N,Scalici V,Arrigo R,Bellia V

更新日期：2013-08-01 00:00:00

abstract：BACKGROUND:Proper adjustment of arterial oxygen saturation (SaO2) during daily activities in patients with interstitial lung disease (ILD) requiring long-term oxygen therapy is challenging. Given the multifactorial nature of the limited exercise tolerance in patients with ILDs, the isolated use of oxygen therapy may no...

journal_title：Therapeutic advances in respiratory disease

authors： Cuerpo S,Palomo M,Hernández-González F,Francesqui J,Albacar N,Hernández C,Blanco I,Embid C,Sellares J

更新日期：2020-01-01 00:00:00

abstract：:The use of biomarkers on pleural fluid (PF) specimens may assist the decision-making process and enhance clinical diagnostic pathways. Three paradigmatic examples are heart failure, tuberculosis and, particularly, malignancy. An elevated PF concentration of the amino-terminal fragment of probrain natriuretic peptide (...

journal_title：Therapeutic advances in respiratory disease

authors： Porcel JM

更新日期：2018-01-01 00:00:00

abstract：BACKGROUND:Acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF) is well known as a life-threatening condition during its clinical course. However, the clinical features and prognosis in AE of unclassifiable idiopathic interstitial pneumonia (AE-UCIIP) remain to be elucidated. The aim of this study was to clarif...

journal_title：Therapeutic advances in respiratory disease

authors： Enomoto N,Naoi H,Aono Y,Katsumata M,Horiike Y,Yasui H,Karayama M,Hozumi H,Suzuki Y,Furuhashi K,Fujisawa T,Inui N,Nakamura Y,Suda T

更新日期：2020-01-01 00:00:00

abstract：:Pregnancy may be complicated by new onset or preexisting asthma. This article reviews the recognition and management of asthma during pregnancy, as well as general principles of asthma medication use during pregnancy. ...

journal_title：Therapeutic advances in respiratory disease

authors： Namazy JA,Schatz M

更新日期：2014-08-01 00:00:00

abstract：:Immunotherapy has significantly altered the treatment landscape for many cancers, including non-small cell lung cancer (NSCLC). Currently approved immuno-oncology agents for lung cancer are aimed at the reversal of immune checkpoints, programmed death protein-1 (PD-1) and programmed death ligand-1 (PD-L1). Although re...

journal_title：Therapeutic advances in respiratory disease

authors： Villanueva N,Bazhenova L

更新日期：2018-01-01 00:00:00

abstract：:Chronic obstructive pulmonary disease (COPD) is a chronic condition that negatively affects several patient-centered outcomes. Among these, exercise capacity, dyspnea, and quality of life are the most relevant. In this article, factors contributing to exercise limitation, increase in exercise-induced dyspnea, quality ...

journal_title：Therapeutic advances in respiratory disease

authors： de Blasio F,Polverino M

更新日期：2012-08-01 00:00:00

abstract：:Background We wanted to determine the impact of combined Clinical Pulmonary Infection Score (CPIS) and a spot serum procalcitonin (PCT)-guided protocol to shorten the duration of antibiotic treatment in patients with ventilator-associated pneumonia (VAP), mainly caused by nonfermentative gram-negative bacilli (NF-GNB)...

journal_title：Therapeutic advances in respiratory disease

authors： Wongsurakiat P,Tulatamakit S

更新日期：2018-01-01 00:00:00

abstract：:Fluoroquinolones are commonly used to treat lung infections in patients with cystic fibrosis. These patients are susceptible to lung infection with common bacteria such as Staphylococcus aureus and Haemophilus influenzae, but are also prone to infection by opportunistic bacteria, including Pseudomonas aeruginosa. The ...

journal_title：Therapeutic advances in respiratory disease

authors： Hurley M,Smyth A

更新日期：2012-12-01 00:00:00

abstract：:Maintenance pharmacological treatment for stable chronic obstructive pulmonary disease (COPD) is based on inhaled drugs, including long-acting muscarinic receptor antagonists (LAMA), long-acting β2-adrenoceptor agonists (LABA) and inhaled corticosteroids (ICS). Inhaled pharmacological treatment can improve patients' d...

journal_title：Therapeutic advances in respiratory disease

authors： Malerba M,Nardin M,Santini G,Mores N,Radaeli A,Montuschi P

更新日期：2018-01-01 00:00:00

abstract：:There is evidence of aberrations in the vitamin D-endocrine system in subjects with respiratory diseases. Vitamin D deficiency is highly prevalent in patients with respiratory diseases, and patients who receive vitamin D have significantly larger improvements in inspiratory muscle strength and maximal oxygen uptake. S...

journal_title：Therapeutic advances in respiratory disease

authors： Luong KV,Nguyen LT

更新日期：2013-12-01 00:00:00

abstract：:Allergen-specific immunotherapy remains the most likely effective treatment modality for allergic disorders by targeting the underlying immune mechanisms and possibly causing modifications in the disease course, as well as treating the symptoms. Treatment and compliance experiences been gained over nearly a century in...

journal_title：Therapeutic advances in respiratory disease

authors： Ozdemir C

更新日期：2009-10-01 00:00:00

abstract：:One of the great challenges of lung transplantation is to bridge the dichotomy between supply and demand of donor organs so that the maximum number of potential recipients achieve a meaningful benefit in improvements in survival and quality of life. To achieve this laudable goal is predicated on choosing candidates wh...

journal_title：Therapeutic advances in respiratory disease

authors： Mitchell AB,Glanville AR

更新日期：2019-01-01 00:00:00

abstract：:As our understanding of the pathobiology and natural history of the various forms of interstitial lung disease (ILD) has evolved, so have our approaches to treating this heterogeneous group of lung disorders. The earliest pharmacologic agents used to treat various forms of ILD were corticosteroids, and corticosteroids...

journal_title：Therapeutic advances in respiratory disease

authors： Kim R,Meyer KC

更新日期：2008-10-01 00:00:00

abstract：:Rheumatoid arthritis (RA) is an inflammatory autoimmune disease that can present different extrarticular manifestations involving heart, lungs and kidneys. In recent years there has been a growing awareness of the central role played by the lungs in the onset and progression of RA. In particular interstitial lung dise...

journal_title：Therapeutic advances in respiratory disease

authors： Picchianti Diamanti A,Markovic M,Argento G,Giovagnoli S,Ricci A,Laganà B,D'Amelio R

更新日期：2017-01-01 00:00:00

abstract：:Programmed cell death (PD)-1 immune checkpoint inhibitors have emerged as promising options for the treatment of multiple cancer types. Nivolumab is a fully human immunoglobulin G4 monoclonal antibody, which inhibits the PD-1 receptor and has been approved in the United States, Europe, and Asia for the treatment of ad...

journal_title：Therapeutic advances in respiratory disease

authors： Hida T

更新日期：2018-01-01 00:00:00